Oppenheimer lowered the firm’s price target on Nurix Therapeutics (NRIX) to $32 from $35 and keeps an Outperform rating on the shares following quarterly results. The firm is updating opex estimates based on guidance from management. Oppenheimer believes the company’s cash position of about $550M and strategic collaborations can sustain operations into the first half of 2027.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NRIX:
- Nurix Therapeutics price target lowered to $25 from $32 at Wells Fargo
- Nurix Therapeutics price target lowered to $35 from $36 at Stifel
- Nurix Therapeutics: Strong Financials and Strategic Collaborations Support ‘Buy’ Rating
- Promising Developments and Strategic Partnerships Propel Nurix Therapeutics: A Buy Recommendation
- Nurix Therapeutics, Inc. Earnings Report: Is it a Beat?
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue